deferoxamine has been researched along with Aging in 36 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferoxamine (DFX) reduces brain edema, neurological deficits, and brain atrophy after intracerebral hemorrhage (ICH) in aged and young rats." | 7.76 | Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration. ( Hua, Y; Keep, RF; Morgenstern, LB; Okauchi, M; Schallert, T; Xi, G, 2010) |
| "N(epsilon)-(Carboxymethyl)lysine (CML), a major product of oxidative modification of glycated proteins, has been suggested to represent a general marker of oxidative stress and long-term damage to proteins in aging, atherosclerosis, and diabetes." | 7.69 | Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. ( Nerlich, AG; Schleicher, ED; Wagner, E, 1997) |
| "Deferoxamine treatment has different effects on the expression of HSP-27 and HSP-32." | 5.37 | Deferoxamine affects heat shock protein expression in heart after intracerebral hemorrhage in aged rats. ( Hu, H; Hua, Y; Keep, RF; Okauchi, M; Wang, L; Xi, G, 2011) |
| "Deferoxamine (DFX) reduces brain edema, neurological deficits, and brain atrophy after intracerebral hemorrhage (ICH) in aged and young rats." | 3.76 | Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration. ( Hua, Y; Keep, RF; Morgenstern, LB; Okauchi, M; Schallert, T; Xi, G, 2010) |
| "Our primary purpose was to assess the impact of chronic exposure to dietary aluminum on aging rats." | 3.69 | Aluminum retention by aged rats fed aluminum and treated with desferrioxamine. ( Ecelbarger, CA; Greger, JL; MacNeil, GG, 1994) |
| "N(epsilon)-(Carboxymethyl)lysine (CML), a major product of oxidative modification of glycated proteins, has been suggested to represent a general marker of oxidative stress and long-term damage to proteins in aging, atherosclerosis, and diabetes." | 3.69 | Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. ( Nerlich, AG; Schleicher, ED; Wagner, E, 1997) |
| "Deferoxamine treatment has different effects on the expression of HSP-27 and HSP-32." | 1.37 | Deferoxamine affects heat shock protein expression in heart after intracerebral hemorrhage in aged rats. ( Hu, H; Hua, Y; Keep, RF; Okauchi, M; Wang, L; Xi, G, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (13.89) | 18.7374 |
| 1990's | 12 (33.33) | 18.2507 |
| 2000's | 6 (16.67) | 29.6817 |
| 2010's | 9 (25.00) | 24.3611 |
| 2020's | 4 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, YN | 1 |
| Wang, HH | 1 |
| Su, CH | 1 |
| Lee, HI | 1 |
| Chou, YH | 1 |
| Hsieh, CL | 1 |
| Liu, WT | 1 |
| Shu, KT | 1 |
| Chang, KT | 1 |
| Yeh, HI | 1 |
| Wu, YJ | 1 |
| Mielke, N | 1 |
| Johnson, S | 1 |
| Bahl, A | 1 |
| Fadladdin, YAJ | 1 |
| Xue, M | 1 |
| Zhang, X | 1 |
| Chen, J | 1 |
| Liu, F | 1 |
| Xu, J | 1 |
| Xie, J | 1 |
| Yang, Y | 1 |
| Yu, W | 1 |
| Qiu, H | 1 |
| Xue, J | 1 |
| Jiang, J | 1 |
| Liu, Y | 2 |
| Shallom, SJ | 1 |
| Zelazny, AM | 1 |
| Giri, AR | 1 |
| Kaur, N | 1 |
| Yarrarapu, SNS | 1 |
| Rottman Pietrzak, KA | 1 |
| Santos, C | 1 |
| Lowman, PE | 1 |
| Niaz, S | 1 |
| Franco, PM | 1 |
| Sanghavi, DK | 1 |
| Zhu, D | 1 |
| Liang, R | 1 |
| Li, Z | 2 |
| Cheng, L | 1 |
| Ren, J | 1 |
| Guo, Y | 1 |
| Wang, M | 1 |
| Chai, H | 1 |
| Niu, Q | 1 |
| Yang, S | 1 |
| Bai, J | 1 |
| Yu, H | 1 |
| Zhang, H | 1 |
| Qin, X | 1 |
| Sahrakorpi, N | 1 |
| Engberg, E | 1 |
| Stach-Lempinen, B | 1 |
| Tammelin, TH | 1 |
| Kulmala, J | 1 |
| Roine, RP | 1 |
| Koivusalo, SB | 1 |
| Cheng, W | 1 |
| Pang, H | 1 |
| Campen, MJ | 1 |
| Zhang, J | 2 |
| Li, Y | 1 |
| Gao, J | 1 |
| Ren, D | 1 |
| Ji, X | 1 |
| Rothman, N | 1 |
| Lan, Q | 1 |
| Zheng, Y | 1 |
| Leng, S | 1 |
| Hu, Z | 1 |
| Tang, J | 1 |
| Dong, Q | 1 |
| Song, N | 1 |
| Qin, N | 1 |
| Chen, C | 1 |
| Sun, X | 1 |
| Easton, J | 1 |
| Mulder, H | 1 |
| Plyler, E | 1 |
| Neale, G | 1 |
| Walker, E | 1 |
| Li, Q | 1 |
| Ma, X | 1 |
| Chen, X | 1 |
| Huang, IC | 1 |
| Yasui, Y | 1 |
| Ness, KK | 1 |
| Hudson, MM | 1 |
| Robison, LL | 1 |
| Wang, Z | 1 |
| Subota, A | 1 |
| Spotswood, N | 1 |
| Roach, M | 1 |
| Goodarzi, Z | 1 |
| Holroyd-Leduc, J | 1 |
| Park, EA | 1 |
| Graves, SA | 1 |
| Menda, Y | 1 |
| Bloomer, SA | 4 |
| Lapenna, D | 1 |
| Ciofani, G | 1 |
| Pierdomenico, SD | 1 |
| Giamberardino, MA | 1 |
| Porreca, E | 1 |
| Brown, KE | 3 |
| Kregel, KC | 3 |
| Ricchi, P | 1 |
| Ammirabile, M | 1 |
| Costantini, S | 2 |
| Spasiano, A | 1 |
| Di Matola, T | 1 |
| Cinque, P | 1 |
| Casale, M | 1 |
| Filosa, A | 2 |
| Prossomariti, L | 1 |
| Han, O | 1 |
| Ni, W | 1 |
| Okauchi, M | 4 |
| Hatakeyama, T | 2 |
| Gu, Y | 1 |
| Keep, RF | 4 |
| Xi, G | 4 |
| Hua, Y | 4 |
| Sorond, FA | 1 |
| Tan, CO | 1 |
| LaRose, S | 1 |
| Monk, AD | 1 |
| Fichorova, R | 1 |
| Ryan, S | 1 |
| Lipsitz, LA | 1 |
| Kang, LS | 1 |
| Reyes, RA | 1 |
| Muller-Delp, JM | 1 |
| Morgenstern, LB | 1 |
| Schallert, T | 1 |
| Hu, H | 1 |
| Wang, L | 1 |
| Valentini, S | 1 |
| Cabreiro, F | 1 |
| Ackerman, D | 1 |
| Alam, MM | 1 |
| Kunze, MB | 1 |
| Kay, CW | 1 |
| Gems, D | 1 |
| Tanguy, S | 1 |
| de Leiris, J | 1 |
| Besse, S | 1 |
| Boucher, F | 1 |
| Yoon, YS | 1 |
| Byun, HO | 1 |
| Cho, H | 1 |
| Kim, BK | 1 |
| Yoon, G | 1 |
| de Lima, MN | 1 |
| Dias, CP | 1 |
| Torres, JP | 1 |
| Dornelles, A | 1 |
| Garcia, VA | 1 |
| Scalco, FS | 1 |
| Guimarães, MR | 1 |
| Petry, RC | 1 |
| Bromberg, E | 1 |
| Constantino, L | 1 |
| Budni, P | 1 |
| Dal-Pizzol, F | 1 |
| Schröder, N | 1 |
| Buettner, GR | 1 |
| Silvestroni, E | 1 |
| Bianco, I | 1 |
| Graziani, B | 1 |
| Lerone, M | 1 |
| Valente, M | 1 |
| Congedo, P | 1 |
| Ponzini, D | 1 |
| Piomelli, S | 1 |
| Graziano, J | 1 |
| Dang, S | 1 |
| Rasmussen, CA | 1 |
| LeVine, SM | 1 |
| Ecelbarger, CA | 1 |
| MacNeil, GG | 1 |
| Greger, JL | 1 |
| Crowe, A | 1 |
| Morgan, EH | 2 |
| Schleicher, ED | 1 |
| Wagner, E | 1 |
| Nerlich, AG | 1 |
| Rikans, LE | 1 |
| Ardinska, V | 1 |
| Hornbrook, KR | 1 |
| Jensen, PD | 1 |
| Olsen, N | 1 |
| Bagger, JP | 1 |
| Jensen, FT | 1 |
| Christensen, T | 1 |
| Ellegaard, J | 1 |
| Papadopoulos, MC | 1 |
| Koumenis, IL | 1 |
| Yuan, TY | 1 |
| Giffard, RG | 1 |
| Moos, T | 1 |
| Caruso-Nicoletti, M | 1 |
| De Sanctis, V | 1 |
| Capra, M | 1 |
| Cardinale, G | 1 |
| Cuccia, L | 1 |
| Di Gregorio, F | 1 |
| Galati, MC | 1 |
| Lauriola, A | 1 |
| Malizia, R | 1 |
| Mangiagli, A | 1 |
| Massolo, F | 1 |
| Mastrangelo, C | 1 |
| Meo, A | 1 |
| Messina, MF | 1 |
| Ponzi, G | 1 |
| Raiola, G | 1 |
| Ruggiero, L | 1 |
| Tamborino, G | 1 |
| Saviano, A | 1 |
| Gómez, M | 2 |
| Esparza, JL | 2 |
| Domingo, JL | 2 |
| Singh, PK | 1 |
| Jones, MM | 1 |
| del Castillo, D | 1 |
| Hernández, M | 1 |
| Viteri, FE | 1 |
| García-Ibañez, R | 1 |
| Torún, B | 1 |
| Nakamura, H | 1 |
| del Nido, PJ | 1 |
| Jimenez, E | 1 |
| Sarin, M | 1 |
| Feinberg, H | 1 |
| Levitsky, S | 1 |
| Frank, L | 1 |
| Perez-Infante, V | 1 |
| Bardin, CW | 1 |
| Gunsalus, GL | 1 |
| Musto, NA | 1 |
| Rich, KA | 1 |
| Mather, JP | 1 |
| Hoffbrand, AV | 1 |
| Broitman, SA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hypoxia-Inducible Transcription Factor 1 (HIF-1)in Vascular Aging[NCT01365104] | Early Phase 1 | 97 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Safety and Effectiveness Study of Deferoxamine and Xingnaojing Injection in Intracerebral Hemorrhage[NCT02367248] | Phase 1/Phase 2 | 180 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
| Study of Deferoxamine Mesylate in Intracerebral Hemorrhage[NCT02175225] | Phase 2 | 294 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Adverse event of special interest: anaphylaxis at any time during the study infusion (NCT02175225)
Timeframe: during the study infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 3 |
| Normal Saline | 0 |
Hypotension requiring medical intervention at any time during the study infusion that could not be explained by other causes (NCT02175225)
Timeframe: during the study infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 1 |
| Normal Saline | 2 |
Adverse event of special interest: development of new and unexplained visual or auditory changes after initiation of the study infusion (NCT02175225)
Timeframe: after initiation of study infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 3 |
| Normal Saline | 4 |
Edema accompanied by an unexplained increase of more than four points on the US National Institutes of Health Stroke Scale or a decrease of more than two points in Glasgow Coma Scale score during the first week after the intracerebral haemorrhage. (NCT02175225)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 9 |
| Normal Saline | 5 |
Number of subjects experiencing Serious adverse events at any time from randomization through day 90 (NCT02175225)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 39 |
| Normal Saline | 49 |
Number of Subjects Experiencing Serious Adverse Events within 7 days of randomization (NCT02175225)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 24 |
| Normal Saline | 26 |
Another measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 180 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome. (NCT02175225)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 61 |
| Normal Saline | 48 |
The primary outcome measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 90 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome. (NCT02175225)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 48 |
| Normal Saline | 47 |
Another measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-3 at 180 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome. (NCT02175225)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 97 |
| Normal Saline | 92 |
"Another measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-3 at 90 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome.~Although mRS 0-3 is less favorable than the primary outcome of mRS 0-2, it would still be a desirable effect in patients with ICH given that no treatments exist to reduce disability." (NCT02175225)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine Mesylate | 91 |
| Normal Saline | 82 |
Adverse event of special interest: Respiratory compromise of any cause, including acute respiratory distress syndrome, in hospital until day 7 or discharge [whichever was earlier] (NCT02175225)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| All cause | Cause by acute respiratory distress syndrome | |
| Deferoxamine Mesylate | 20 | 2 |
| Normal Saline | 23 | 1 |
Analyses will be expanded to include an interaction between treatment and OTT window and the magnitude of the treatment effect, and corresponding confidence interval, will be estimated for each time window (<12 hours vs. >/= 12 hours) in order to explore the presence of a differential treatment effect in the OTT windows. (NCT02175225)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Onset to treatment time <=12 hours | Onset to treatment time >12 hours | |
| Deferoxamine Mesylate | 15 | 33 |
| Normal Saline | 19 | 28 |
1 review available for deferoxamine and Aging
| Article | Year |
|---|---|
Topics: Adult; Aging; Aluminum; Alzheimer Disease; Animals; Anti-Bacterial Agents; Artemisia annua; Body Mas | 2022 |
1 trial available for deferoxamine and Aging
| Article | Year |
|---|---|
Deferoxamine, Cerebrovascular Hemodynamics, and Vascular Aging: Potential Role for Hypoxia-Inducible Transcription Factor-1-Regulated Pathways.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Cerebrovascular Circulation; Chelation Therapy; C | 2015 |
34 other studies available for deferoxamine and Aging
| Article | Year |
|---|---|
Deferoxamine accelerates endothelial progenitor cell senescence and compromises angiogenesis.
Topics: Aging; Animals; Cell Proliferation; Cells, Cultured; Cellular Senescence; Deferoxamine; Endothelial | 2021 |
Hepatic Macrophage Abundance and Phenotype in Aging and Liver Iron Accumulation.
Topics: Aging; Animals; Deferoxamine; Iron; Liver; Macrophages; Phenotype; Rats; Rats, Inbred F344 | 2022 |
Iron status and oxidative stress in the aged rabbit heart.
Topics: Aging; Animals; Deferoxamine; Hemodynamics; Hydroxyquinolines; Iron; Lipid Peroxidation; Myocardium; | 2018 |
Renal Iron Accumulation and Oxidative Injury With Aging: Effects of Treatment With an Iron Chelator.
Topics: Aging; Animals; Antioxidants; Autophagy; Deferoxamine; Iron; Iron Chelating Agents; Kidney; Male; Mi | 2020 |
Nephrolithiasis in patients exposed to deferasirox and desferioxamine: probably an age-linked event with different effects on some renal parameters.
Topics: Adult; Aging; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferoxamine; Disease Sus | 2014 |
Altered expression of iron regulatory proteins with aging is associated with transient hepatic iron accumulation after environmental heat stress.
Topics: Aging; Animals; Cation Transport Proteins; Deferoxamine; Gene Expression; Heat-Shock Response; Hot T | 2014 |
Deferoxamine reduces intracerebral hemorrhage-induced white matter damage in aged rats.
Topics: Aging; Analysis of Variance; Animals; Cerebral Hemorrhage; Deferoxamine; Disease Models, Animal; Dos | 2015 |
Aging impairs flow-induced dilation in coronary arterioles: role of NO and H(2)O(2).
Topics: Aging; Animals; Antioxidants; Arterioles; Catalase; Coronary Circulation; Cyclic N-Oxides; Deferoxam | 2009 |
Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration.
Topics: Aging; Animals; Atrophy; Brain Edema; Caudate Nucleus; Cerebral Hemorrhage; Deferoxamine; Disease Mo | 2010 |
Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration.
Topics: Aging; Animals; Atrophy; Brain Edema; Caudate Nucleus; Cerebral Hemorrhage; Deferoxamine; Disease Mo | 2010 |
Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration.
Topics: Aging; Animals; Atrophy; Brain Edema; Caudate Nucleus; Cerebral Hemorrhage; Deferoxamine; Disease Mo | 2010 |
Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration.
Topics: Aging; Animals; Atrophy; Brain Edema; Caudate Nucleus; Cerebral Hemorrhage; Deferoxamine; Disease Mo | 2010 |
Deferoxamine reduces cavity size in the brain after intracerebral hemorrhage in aged rats.
Topics: Aging; Animals; Antigens, Differentiation; Behavior, Animal; Brain Infarction; Cell Count; Cerebral | 2011 |
Deferoxamine affects heat shock protein expression in heart after intracerebral hemorrhage in aged rats.
Topics: Aging; Analysis of Variance; Animals; Cerebral Hemorrhage; Deferoxamine; Gene Expression Regulation; | 2011 |
Manipulation of in vivo iron levels can alter resistance to oxidative stress without affecting ageing in the nematode C. elegans.
Topics: Aging; Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Cells, Cultured; Deferoxami | 2012 |
Ageing exacerbates the cardiotoxicity of hydrogen peroxide through the Fenton reaction in rats.
Topics: Aging; Animals; Deferoxamine; Hydrogen Peroxide; Hydroxyl Radical; Iron; Iron Chelating Agents; Male | 2003 |
Complex II defect via down-regulation of iron-sulfur subunit induces mitochondrial dysfunction and cell cycle delay in iron chelation-induced senescence-associated growth arrest.
Topics: Adenosine Triphosphate; Aging; Cell Cycle; Cells, Cultured; Deferoxamine; Down-Regulation; Electron | 2003 |
Reversion of age-related recognition memory impairment by iron chelation in rats.
Topics: Aging; Animals; Brain; Deferoxamine; Iron; Memory Disorders; Rats; Rats, Wistar; Recognition, Psycho | 2008 |
Dysregulation of hepatic iron with aging: implications for heat stress-induced oxidative liver injury.
Topics: Age Factors; Aging; Animals; Deferoxamine; Disease Models, Animal; Ferritins; Heat Stress Disorders; | 2008 |
Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.
Topics: Adolescent; Adult; Aging; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Feces; Female; F | 1982 |
Reduction of iron overload in thalassemia.
Topics: Adolescent; Adult; Aging; Animals; Cell Separation; Child; Child, Preschool; Deferoxamine; Erythrocy | 1982 |
Immunocytochemical localization of desferrioxamine in the kidney, liver and brain of the developing and adult mouse: implications for drug processing and therapeutic mechanisms.
Topics: Aging; Animals; Brain; Deferoxamine; Immune Sera; Injections, Intraperitoneal; Injections, Intravent | 1994 |
Aluminum retention by aged rats fed aluminum and treated with desferrioxamine.
Topics: Aging; Aluminum; Analysis of Variance; Animals; Bone Remodeling; Deferoxamine; Hydroxyproline; Male; | 1994 |
Effects of chelators on iron uptake and release by the brain in the rat.
Topics: 2,2'-Dipyridyl; Aging; Animals; Biological Transport; Bone and Bones; Brain; Deferiprone; Deferoxami | 1994 |
Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging.
Topics: Adult; Aged; Aging; Antibodies; Arteries; Arteriosclerosis; Biomarkers; Blood Proteins; Catalase; Ch | 1997 |
Age-associated increase in ferritin content of male rat liver: implication for diquat-mediated oxidative injury.
Topics: Aging; Animals; Deferoxamine; Diquat; Ferritins; Iron; Kinetics; Lipid Peroxidation; Liver; Male; Mi | 1997 |
Cardiac function during iron chelation therapy in adult non-thalassaemic patients with transfusional iron overload.
Topics: Adolescent; Adult; Aged; Aging; Antidotes; Ascorbic Acid; beta-Thalassemia; Chelating Agents; Corona | 1997 |
Increasing vulnerability of astrocytes to oxidative injury with age despite constant antioxidant defenses.
Topics: Aging; Animals; Antioxidants; Astrocytes; Blotting, Western; Catalase; Deferoxamine; Glucose; Glutat | 1998 |
Evidence for low molecular weight, non-transferrin-bound iron in rat brain and cerebrospinal fluid.
Topics: Aging; Animals; Binding Sites; Biological Transport; Blood-Brain Barrier; Body Weight; Brain; Defero | 1998 |
Short stature and body proportion in thalassaemia.
Topics: Adolescent; Adult; Aging; beta-Thalassemia; Blood Transfusion; Body Constitution; Body Height; Child | 1998 |
Chelation therapy in aluminum-loaded rats: influence of age.
Topics: Aging; Aluminum; Animals; Antidotes; Chelating Agents; Chelation Therapy; Deferiprone; Deferoxamine; | 1999 |
Age-Related differences on aluminium mobilization by chelating agents in aluminium-loaded uraemic rats.
Topics: Administration, Oral; Aging; Aluminum; Aluminum Compounds; Animals; Anthelmintics; Chelating Agents; | 2000 |
Sodium iron NaFeEDTA as an iron fortification compound in Central America. Absorption studies.
Topics: Absorption; Adult; Aging; Ascorbic Acid; Central America; Child, Preschool; Deferoxamine; Edetic Aci | 1978 |
Age-related differences in cardiac susceptibility to ischemia/reperfusion injury. Response to deferoxamine.
Topics: Adenine Nucleotides; Aging; Animals; Animals, Newborn; Deferoxamine; Myocardial Contraction; Myocard | 1992 |
Hyperoxic inhibition of newborn rat lung development: protection by deferoxamine.
Topics: Aging; Animals; Animals, Newborn; Deferoxamine; Lung; Oxygen; Rats; Rats, Inbred Strains | 1991 |
Differential regulation of testicular transferrin and androgen-binding protein secretion in primary cultures of rat Sertoli cells.
Topics: Aging; Androgen-Binding Protein; Animals; Blood; Cell Count; Cells, Cultured; Deferoxamine; Epiderma | 1986 |
Effect of chronic nutritional iron deficiency on the small intestinal disaccharidase activities of growing dogs.
Topics: Aging; Animals; Deferoxamine; Deficiency Diseases; Dogs; Galactosidases; Glucosidases; Glycoside Hyd | 1969 |